论文部分内容阅读
如众所知,KIT酪氨酸激酶受体持续活化在胃肠道基底细胞癌发病中起关键作用。临床前期研究表明,选择性酪氨酸激酶受体抑制剂Imatinib对治疗胃肠道基底细胞癌可能有益。本文拟就Imatinib治疗胃肠道基底细胞癌相关药效与安全性进行了评估。对象与方法 147例重度胃肠道基底细胞癌患者,其中144例(98％)已接受过手术治疗,75例(51％)因手术无法根治或肿瘤转移而接受过化学药物治疗,22例(15％)接受
As we all know, KIT tyrosine kinase receptor sustained activation plays a key role in the pathogenesis of gastrointestinal basal cell carcinoma. Preclinical studies have shown that Imatinib, a selective tyrosine kinase receptor inhibitor, may be useful for the treatment of gastrointestinal basal cell carcinoma. This article is intended to evaluate the efficacy and safety of Imatinib in the treatment of gastrointestinal basal cell carcinoma. Subjects and Methods A total of 147 patients with severe gastrointestinal basal cell carcinoma, of whom 144 (98%) had undergone surgical treatment and 75 (51%) had received chemical drug therapy because of an incurable or tumor metastasis. Twenty-two 15%) accepted